Loading…
Cogent Biosciences, Inc. is projected to rise to $52.37 by 2027, a +27% move from its current price of $41.36. COGT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $40.53 | $41.36 | $42.21 | 0.00% |
| Aug 2 | $40.19 | $41.36 | $42.57 | +0.01% |
| Aug 3 | $39.93 | $41.37 | $42.85 | +0.01% |
| Aug 4 | $39.72 | $41.37 | $43.09 | +0.02% |
| Aug 5 | $39.53 | $41.37 | $43.30 | +0.02% |
| Aug 6 | $39.36 | $41.37 | $43.49 | +0.03% |
| Aug 7 | $39.20 | $41.37 | $43.66 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $39.20 | $41.37 | $43.66 | +0.03% |
| Week 2 | $38.35 | $41.39 | $44.66 | +0.06% |
| Week 3 | $37.71 | $41.40 | $45.45 | +0.09% |
| Week 4 | $37.18 | $41.41 | $46.12 | +0.12% |
| Week 5 | $36.72 | $41.42 | $46.73 | +0.15% |
| Week 6 | $36.32 | $41.44 | $47.28 | +0.19% |
| Week 7 | $35.94 | $41.45 | $47.80 | +0.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases.
Its lead product candidate bezuclastinib (CGT9486) is a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Cogent also develops CGT4859, a reversible and selective FGFR2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Cogent Biosciences, Inc. (COGT) is a Healthcare company with a current price of $41.36, a market cap of $7.07B, and a rank of 1062.
The stock trades with a bullish technical backdrop, supported by a 50-day simple moving average of $36.35 and a 200-day simple moving average of $34.62, and a current price near resistance at $41.36.
The 30-day range spans $36.17 to $47.30, with a listed support at $33.67. Annualized volatility is 40 and the sentiment is labeled BULLISH.
A major floor 25.0% below — a decisive break under it would weaken the trend.
The nearest floor, 18.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 12.4% above — clearing it would confirm fresh momentum.
Key COGT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COGT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.36 | Buy | $40.42 | Buy |
| MA 10 | $39.86 | Buy | $39.98 | Buy |
| MA 20 | $39.46 | Buy | $39.21 | Buy |
| MA 50 | $36.35 | Buy | $37.57 | Buy |
| MA 100 | $36.03 | Buy | $36.18 | Buy |
| MA 200 | $34.62 | Buy | $32.42 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.68 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 166.34 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 7.40 | Buy |
| Bollinger %B (20,2) | 1.00 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.43 | Buy |
| Awesome (5,34) | 2.38 | Buy |
| Ultimate (7,14,28) | 64.72 | Neutral |
| Momentum (10) | 3.42 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 40.68 | Buy |
| ADX (14) | 22.71 | Buy |
| ATR (14) | 0.81 | Info |
The 30-day technical picture is bullish, with RSI14 at 60 and the price trading above the SMA50 of $36.35 and near the SMA200 of $34.62.
Key near-term levels are support at $33.67 and resistance at $41.36, with the 30-day range from $36.17 to $47.30.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $31.02 | $41.36 | $53.49 | 0% | Neutral | |
| $42.72 | $52.37 | $67.22 | +27% | Bullish | |
| $51.40 | $64.30 | $84.97 | +55% | Bullish | |
| $54.04 | $68.75 | $92.95 | +66% | Bullish | |
| $62.85 | $81.14 | $111.83 | +96% | Bullish | |
| $78.77 | $103.05 | $144.43 | +149% | Bullish | |
| $91.94 | $121.78 | $173.29 | +194% | Bullish | |
| $107.66 | $144.26 | $208.11 | +249% | Bullish | |
| $115.67 | $156.68 | $228.92 | +279% | Bullish | |
| $121.55 | $166.35 | $245.94 | +302% | Bullish | |
| $214.17 | $306.99 | $477.07 | +642% | Bullish | |
| $380.19 | $588.81 | $984.91 | +13.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $31.02 | $41.36 | $48.19 | +0.00% |
| August 2026 | $35.44 | $41.37 | $49.25 | +0.03% |
| September 2026 | $35.35 | $41.53 | $49.94 | +0.38% |
| October 2026 | $36.34 | $42.89 | $52.00 | +3.29% |
| November 2026 | $36.80 | $43.62 | $53.22 | +1.68% |
| December 2026 | $36.63 | $43.58 | $53.49 | -0.08% |
Click any year to see its month-by-month COGT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect COGT to range from $31.02 to $53.49 through 2026. The $41.36 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The COGT price prediction for 2027 points to an average of $52.37 (low $42.72, high $67.22) — a potential gain of +27% on today's $41.36. Buyers look set to stay in control over this stretch.
In 2028, COGT is projected to trade between $51.40 and $84.97, averaging $64.30 — a potential gain of +55% from today's $41.36. That is up +23% on the projected 2027 average. Momentum favours further upside here.
Cogent Biosciences, Inc.'s 2029 outlook centres on $68.75, within a $54.04 to $92.95 range. That is up +7% on the projected 2028 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, COGT could reach as high as $111.83, with a base case around $81.14 and support toward $62.85 — roughly +96% from $41.36. Momentum favours further upside here.
Expect COGT to range from $78.77 to $144.43 through 2031. The $103.05 average target implies a +149% move from current prices. That is up +27% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The COGT price prediction for 2032 points to an average of $121.78 (low $91.94, high $173.29) — a potential gain of +194% on today's $41.36. Momentum favours further upside here.
In 2033, COGT is projected to trade between $107.66 and $208.11, averaging $144.26 — a potential gain of +249% from today's $41.36. That is up +18% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Cogent Biosciences, Inc.'s 2034 outlook centres on $156.68, within a $115.67 to $228.92 range. That is up +9% on the projected 2033 average. That marks a +279% change versus current levels. Momentum favours further upside here.
By 2035, COGT could reach as high as $245.94, with a base case around $166.35 and support toward $121.55 — roughly +302% from $41.36. Buyers look set to stay in control over this stretch.
Expect COGT to range from $214.17 to $477.07 through 2040. The $306.99 average target implies a +642% move from current prices. That is up +85% on the projected 2035 average. Momentum favours further upside here.
The COGT price prediction for 2050 points to an average of $588.81 (low $380.19, high $984.91) — a potential gain of +13.2x on today's $41.36. Buyers look set to stay in control over this stretch.
Investing $1,000 in COGT today (≈ 24.17795 COGT) could be worth
$14,236.25
+$13,236.25 (+1324%) by 2050 · US Dollar
Based on the average projected COGT price of $588.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COGTwould be worth at today's price.
$1,000 invested in COGT on Jul 30, 2025 (≈ 86.730271 COGT) would be worth
$3,587.16
+$2,587.16 (+258.7%) today · 3.59× · US Dollar
Based on a COGT entry price of $11.53 vs. today's $41.36.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $40.24 | $1,027.83 | +2.8% |
| 1 month ago | $38.7 | $1,068.73 | +6.9% |
| 3 months ago | $36.63 | $1,129.13 | +12.9% |
| 6 months ago | $35.91 | $1,151.77 | +15.2% |
| 1 year ago | $11.53 | $3,587.16 | +258.7% |
| All time (5.0y) ago | $5.99 | $6,904.84 | +590.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COGT forecast.
Our base-case forecast reaches $83.00 around 2031.
Implied market cap at $83.00: $14.18B
The multi-year forecast shows a bullish arc through 2050, beginning with a 2026 average price of $41.36 and a neutral stance for that year. The 2026 min is $31.02 and max is $53.49, with ROI 0.
The forecast then climbs over 2027–2035, with 2027 min $42.72, avg $52.37, max $67.22 and ROI 26.6, and continued bullish momentum through 2028 (min $51.40, avg $64.30, max $84.97; ROI 55.5) and 2029 (min $54.04, avg $68.75, max $92.95; ROI 66.2).
In 2030, the forecast shows min $62.85, avg $81.14, max $111.83 with ROI 96.2 and a bullish sentiment.
By 2040, the forecast expands to min $214.17, avg $306.99, max $477.07 with ROI 642.3, still labeled bullish.
The 2050 forecast sits at min $380.19, avg $588.81, max $984.91 with ROI 1323.6 and a bullish outlook. These are estimates, not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows min $62.85, avg $81.14, max $111.83; ROI 96.2; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and ROIs (2027 avg $52.37, ROI 26.6; 2028 avg $64.30, ROI 55.5; 2029 avg $68.75, ROI 66.2; 2030 avg $81.14, ROI 96.2; 2050 avg $588.81, ROI 1323.6), though 2026 is neutral with ROI 0.
Yes. The 2031 forecast shows avg $103.05 and max $144.43, indicating a path above $100 by 2031.
Current price is $41.36 and market cap is $7.07B.
For 2040 the min is $214.17, avg $306.99, max $477.07; ROI 642.3; sentiment BULLISH.
Cogent Biosciences, Inc. Community Discussion
0Share your Cogent Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.